Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

• Status: Completed
• Trial end date: 2018-04-30
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to determine a safe, tolerable and effective dose of sotatercept that results in the greatest frequency of improvement of anemia in patients diagnosed with low- or intermediate-1 risk myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia (CMML).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Celgene; Celgene Corporation
• Treatments: Immunoglobulin G

Criteria

Inclusion Criteria:

• Men and women ≥ 18 years of age

• Documented diagnosis of myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia (CMML), white blood cells (WBC) ≤ 13,000 /mm^3, World Health Organization (WHO) that meets International Prognostic Scoring System (IPSS) criteria for low or intermediate-1 risk disease

• Anemia, Hemoglobin (Hgb) ≤ 9.0 g/dL or ≥ 2 units of Red Blood Cells (RBCs) within 84 days

• No response or loss of response to Erythropoiesis-Stimulating Agents (ESAs) or erythropoetin (EPO) > 500 mU/ml

• Eastern Cooperative Group (ECOG) score ≤2.

• Creatinine < 1.5 * Upper Limit of the Normal (ULN)

• Total bilirubin ≤3.0 mg/dL

• Aspartate aminotransferase (AST)/Serum glutamic oxaloacetic transaminase (SGOT) & Alanine Aminotransferase (ALT)/Serum Glutamic Pyruvic (SGPT) ≤3.0 * Upper Limit of Norma (ULN)

• Free of metastatic malignancy (other than MDS) for ≥2 years

• Highly effective methods of birth control for females and males

Exclusion Criteria:

• Chromosome 5q deletion

• Pregnant or breast feeding women and males who do not agree to use condom during the sexual contact with females of childbearing potential

• Major surgery within 30 days

• Incomplete recovery or incomplete healing of wounds from previous surgery

• Heart failure ≥3 (New York Heart Association (NYHA))

• Thromboembolic or myocardial infarction event within 6 months

• Concurrent anti-cancer cytotoxic chemotherapy

• History of severe allergic or anaphylactic reaction or hypersensitivity to recombinant protein

• Known positive for Human Immunovirus (HIV) or infectious Hepatitis type C or active infectious Hepatitis type B

• Clinically significant anemia unrelated to MDS

• Thrombocytopenia (<30,000/uL)

• Uncontrolled hypertension

• Treatment with another investigational drug or device within 28 days prior to Day 1

• Prior exposure to sotatercept (ACE-011)

• Any serious medical condition, lab abnormality or psychiatric illness